Viridian Therapeutics, Inc./DE — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b537b5ee-976a-44b1-9b01-846d92bc4e95/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $70.8M | 2025-01-01 – 2025-12-31 | evidence 0001590750-26-000007 |
| FY 2024 | $302.0k | 2024-01-01 – 2024-12-31 | evidence 0001590750-25-000004 |
| FY 2023 | $314.0k | 2023-01-01 – 2023-12-31 | evidence 0001590750-24-000007 |
| FY 2022 | $1.8M | 2022-01-01 – 2022-12-31 | evidence 0001590750-23-000002 |
| FY 2021 | $3.0M | 2021-01-01 – 2021-12-31 | evidence 0001590750-22-000004 |
| FY 2020 | $1.1M | 2020-01-01 – 2020-12-31 | evidence 0001590750-21-000029 |
| FY 2019 | $4.5M | 2019-01-01 – 2019-12-31 | evidence 0001590750-20-000021 |
| FY 2018 | $8.4M | 2018-01-01 – 2018-12-31 | evidence 0001590750-19-000013 |
| FY 2017 | $4.0M | 2017-01-01 – 2017-12-31 | evidence 0001590750-19-000013 |
| FY 2016 | $3.5M | 2016-01-01 – 2016-12-31 | evidence 0001590750-18-000006 |
| FY 2015 | $2.5M | 2015-01-01 – 2015-12-31 | evidence 0001171843-16-008702 |
| FY 2014 | $4.3M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001691 |
| FY 2013 | $4.3M | 2013-01-01 – 2013-12-31 | evidence 0001171843-15-001691 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Viridian Therapeutics, Inc./DE — all facts · Net Income · Operating Income